地拉罗司适用于治疗什么病症呢？

What diseases is it suitable for treating? Indications for Deferasirox:

1. Deferasirox can be used to treat reversible renal insufficiency caused by Fanconi syndrome.

2. For the treatment of secondary hemochromatosis.

3. Can be used to treat porphyria cutaneous tarda.

4. For the treatment of myelodysplastic syndrome.

5. Used to treat iron overload caused by blood transfusion in patients with chronic anemia 2 years old and above.

Common adverse reactions of deferasirox in Chinese patients with thalassemia include rash, abdominal pain, diarrhea, increased transaminase, and increased serum muscle intoxication. Most of them are mild, and no serious adverse reactions have been found.

Deferasirox can cause kidney damage and gastrointestinal bleeding, so it is recommended that creatinine clearance should be tested twice before starting treatment, once a week during the first month of treatment, and once a month thereafter.

Gastrointestinal bleeding is a common adverse reaction of this drug and may be fatal in elderly patients with advanced hematological malignancies or thrombocytopenia, and these patients are unlikely to benefit from this drug.

Deferasirox may cause serious adverse reactions such as liver failure. Patients must monitor liver function regularly every month while taking the drug. Once there is an unexplained, persistent or progressive increase in serum aminotransferase levels, the usage of deferasirox should be adjusted or the drug discontinued.

For patients with renal insufficiency, deferasirox can cause an increase in creatinine levels, and 38% of patients have an increase in creatinine levels of more than 33%. However, the increase in creatinine levels caused by deferasirox generally does not exceed the upper limit of normal and has not been reported to cause progressive kidney disease. After dose reduction of deferasirox, creatinine levels returned to normal or remained stable in 13% of patients.

Hearing impairment (hearing loss, hearing loss) and eye diseases (lens opacity, cataracts, increased intraocular pressure, and retinopathy) occur in <1% of patients. Therefore, it is recommended to conduct auditory and visual examinations (including slit lamp examination and fundus examination) before starting iron removal therapy and annually during treatment. Once found, discontinuation should be considered.